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ABSTRACT
The oxidized and reduced forms of ascorbic acid (AA) are reactive and 
unstable compounds making their measurement difficult. Detection of small 
amounts of AA and dehydroascorbic acid (DHAA) is essential for determining 
the biochemical function of the vitamin in cells and subcellular organelles.
While a variety of techniques exist which detect millimolar levels of AA, accurate 
assessment of pmol levels of AA and DHAA in a variety of tissues has not been 
perfected. In the present study, a method was developed for quantitation of AA 
and DHAA that combines HPLC separation with the advantages of increased 
sensitivity and selectivity available with coulometric electrochemical detection.
Tissues were homogenized in 0.3% meta-phosphoric acid containing 1 mM 
thiourea and 0.1 mM EDTA. Portions of the homogenates were either placed in 
10% meta-phosphoric for AA analysis or in a 120 mM sodium phosphate buffer 
(pH 7.2) containing 0.1 mM EDTA and 1 mM thiourea, for total AA (AA +DHAA) 
measurement. Total AA was determined by reducing the endogenous DHAA in 
a sample with 10 mM p-mercaptoethanol and allowing the reduction to occur for 
10 minutes at room temperature. The reaction was stopped with the addition of 
10% meta-phosphoric acid.
The developed method was extended to assess the levels of AA and DHAA 
in nondiabetic and diabetic rat liver, kidney, brain and adrenal tissues. Results 
indicated that the AA levels in diabetic liver and kidney tissues were 
significantly less than control levels but there was no difference in AA levels in 
diabetic and nondiabetic brain and adrenal tissues. When compared to 
controls, DHAA concentration was greater in diabetic rat liver, kidney, and 
adrenal giands but not in brain tissue.
INTRODUCTION
I. History of Ascorbic Acid
Scurvy was first reported in the year 1498 and although awareness of scurvy 
existed for centuries, its cause was unknown. Symptoms of scurvy included 
swelling and bleeding of the gums, swelling of the legs, muscular ache, bone 
pain, weakness, hyperkeratosis, and hemorrhage of small blood vessels.
Scurvy was thought to result from infection, toxication, or faulty diet. Studies 
eliminated the first two possible causes and it was concluded that scurvy was a 
nutritional disease (1).
Results of early studies showed that fat soluble A factor and water soluble B 
factor were essential nutrients. In 1919, Drummond designated a third essential 
nutrient as water soluble C factor (2); this was thought io be the antiscorbutic 
factor sought after for many years. However, it wasn't until 1928 that a 
Hungarian scientist, Albert Szent-Gyorgyi, working at Cambridge, first achieved 
the isolation of vitamin C (3). He observed that there was a high concentration 
of a powerful reducing chemical in the adrenal cortex. From his analysis of the 
crystals isolated from the adrenal cortex, he determined the molecular weight of 
the reducing agent and that the only elements contained in the compound were 
carbon, oxygen, and hydrogen. The ratio of these elements was shown to be 
6 :6 :8 , respectively, and so he gave it the name hexuronic acid. He also isolated 
this powerful reducing agent from cabbage and orange juice, two substances 
known to protect sailors from scurvy. However, there was disagreement as to 
whether hexuronic acid was really the antiscorbutic factor. Most of the
1
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controversy arose because of experiments in which the addition of these 
crystals to experimental guinea pig diets failed to prevent scurvy (4). The 
suggestion was (5) that in their method of preparing the crystals for the animals 
diet, an oxidation step was involved where most of the ascorbic acid (AA) was 
likely lost. In 1932, two separate studies (6, 7) reported that crystals obtained 
from lemon juice, when fed to guinea pigs at 0.5 mg per day, protected them 
from scurvy. This confirmed the initial hypothesis that hexuronic acid was the 
antiscorbutic factor. Hexuronic acid was first synthesized in 1933 by Haworth 
and Hirst (8) and renamed AA. Since that time, understanding the vital 
functions of vitamin C and its availability in food sources has been a major 
nutritional research focus.
II. Metabolism of Vitamin C
The ability to synthesize AA from carbohydrate sources, namely D-glucose 
or D-galactose, through the glucuronic pathway, is retained in a wide variety of 
plant and animal species. The synthetic ability is absent in humans, other 
primates, guinea pigs, insects, invertebrates, fish, and certain bats and birds (9) 
In terms of evolution, the synthesis of AA apparently began in the kidney of 
amphibians and reptiles and was transferred to the liver of mammals but lost in 
guinea pigs, flying mammals, and primates. The inability to synthesize AA 
results from the loss of the genetic material coding for the terminal enzyme, L- 
gulono oxidase (9, 10, 11). Ascorbic acid is required in the diet of species 
deficient in this enzyme.
The intestinal absorption of AA is an active process in scurvy prone animals 
but is a passive process in other animals (12). It was determined that the 
process in scurvy prone animals is that of Na+-dependent coupled-carrier 
transport (12, 13) across the brush border. The active AA absorbance
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mechanism becomes saturated when the concentration of the vitamin is 
increased. This concurs with evidence that the intestinal absorption of AA 
decreases with increasing intake of the vitamin (14). Fresh solutions of 
dehydroascorbic acid (DHAA) were also shown to retain nutritional or 
antiscorbutic activity (4, 15). It was determined that this antiscorbutic activity is 
associated with DHAA's intestinal absorbance that occurs through a process of 
facilitated diffusion across the brush border, and subsequent reduction to AA 
(16,17).
Transport of AA between plasma and tissues was also found to be by an 
active process in most tissues. Dehydroascorbic acid was shown to be the 
preferred form taken up by human neutrophils (18) and erythrocytes (19), and is 
quickly reduced to AA after it is taken up by the cells. Dehydroascorbic acid is 
continuously formed when AA is oxidized in the body. Its concentration is 
maintained at very low levels in tissues by mechanisms that recycle it to AA. 
Compiled tables of AA content in human organs indicate that the pituitary' and 
adrenal glands and the leucocytes contain the highest concentration of AA (20). 
The ocular tissues, brain, liver, and spleen also have relatively high 
concentrations when compared to plasma levels. Plasma levels are 
approximately 0.4-1.0 mg/100 g wet tissue (100 times less than the 
concentration in the pituitary gland). The low levels of AA found in the plasma 
indicate that transfer of the vitamin from plasma to tissue occurs against a 
concentration gradient and therefore must be an active process.
Metabolism of AA and DHAA is governed by a variety of specific and 
nonspecific mechanisms. For example, AA is oxidized to a free radical 
intermediate, semidehydroascorbate or ascorbate free radical (AFR), which is 
detected by electron spin resonance (21, 22). Ascorbate free radical is 
relatively nonreactive when compared to other free radical species. It can either
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react with another AFR to regenerate AA or it can reaci with other radicals to 
terminate their propagation (Fig. 1). An enzyme, AFR reductase, has been 
described in rat liver (23), bovine adrenals, and a variety of rat and guinea pig 
tissues (24, 25). This enzyme reduces the AFR back to AA. In plants, ascorbate 
oxidase (EC 1.10.3.3), a copper containing enzyme, catalyzes the reaction of 
AA and O2 to give DHAA and water (26). In tissues (17, 27, 28, 29) and plants 
(30), dehydroascorbate reductase (EC 1.8.5.1) converts DHAA to AA, using 
glutathione as a reducing agent. Some believe that, in mammals, DHAA is 
converted to AA mainly by nonenzymatic means (31, 32). Dehydroascorbic 
acid is hydrolyzed irreversibly to 2,3-diketogulonic acid (DKG) (Fig. 2), which is 
then rapidly degraded to other products such as xylose, threonic acid, xylonic 
acid, and lyxonic acid.
III. Biochemical Roles of Ascorbic Acid
Ascorbic acid has many diverse roles in the body. Most of these are 
attributed to its reducing and chelating abilities (33). One of its well known 
functions involves the formation of the mature collagen molecule. Ascorbic acid 
serves as a reducing agent for the hydroxylation of proline contained in the 
procollagen molecule (34,35). It is necessary for activation of prolyl 
hydroxylase (36), an Fe++ requiring enzyme that carries out hydroxylation of 
proline. Ascorbic acid presumably keeps Fe++ in its reduced or active state.
Ascorbic acid is also essential for hydroxylation reactions in the biosynthetic 
pathway of muscle carnitine (34, 35, 37). Two of the five steps in the pathway 
involve reactions where AA is required for the enzymes to perform 
hydroxylation. Studies show that vitamin C deficient guinea pigs have low 
carnitine concentrations (38).
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Ascorbic acid also plays a vital role as an antioxidant. Ascorbic acid is 
suggested to play a role in the protection of various tissues against free-radical 
damage induced by various agents including cigarette smoke, radical species 
generated from white blood cells, and photooxidative damage (39). It 
accomplishes this task either directly by reacting with free radicals generated in 
the aqueous phase of the cell, or indirectly by revitalizing the antioxidant 
properties of vitamin E (alpha-tocopherol) (39). Ascorbic acid directly 
scavenges superoxide radical (40, 41), hydroxy free radical (42) and singlet 
oxygen (43) and is an effective inhibitor of lipid peroxidation (39). Lipid 
peroxidation occurs in areas rich in polyunsaturated fatty acids (44). Cell 
membranes contain large amounts of unsaturated fatty acids and are subject to 
damage which could result in cellular death (45) from unchecked peroxidation 
of the membrane lipids. Vitamin E is a fat soluble antioxidant found in the cell 
membranes. !t interrupts the chain reaction that occurs after initial free radical 
attack on a membrane lipid by reacting with the generated lipoxy radical, 
resulting in vitamin E becoming a reactive free radical, the a-tocophero! radical. 
AA regenerates the a-tocopherol radical by reducing it back to a-tocopherol 
(46, 47). In this way, vitamin C protects the antioxidant capacity of vitamin E.
Vitamin C is also required in the nervous system for synthesis of 
norepinephrine. Dopamine-p-hydroxylase is the enzyme that catalyzes the final 
step in the formation of norepinephrine directly from dopamine (48). The 
enzyme requires Cu++ as a cofactor and Cu++ acts as an intermediate 
accepting electrons from AA; then Cu++ transfers the electrons to oxygen to form 
H2O. Ascorbic acid is also involved in the processing of many neuropeptides. 
Ascorbate dependent monooxygenase, called peptidylglycine a-amidating 
monooxygenase (PAM), discovered in the pituitary (49, 50), catalyzes the 
conversion of peptides ending in glycine to their corresponding oc-amidated
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peptide by a mechanism similar to dopamine-p-hydroxylase (51, 52). PAM 
requires Cu++, AA, and O2 for optimal activity. The process of a-amidation of 
peptides is an important mechanism in the biosynthesis of neuroendocrine 
peptides including a-melanocyte stimulating hormone (a-MSH), thyrotropin
releasing hormone, oxytocin, vasopressin, and cholecystokinin (53, 54, 55).
Other roles of vitamin C include detoxification and metabolism of numerous 
compounds, occurring through the cytochrome (P450) mixed function oxidase 
(MFO) system. MFO is found predominantly in liver microsomes and reticulo­
endothelial tissues and is a system which includes enzymes that hydroxylate 
and methylate toxic agents produced by the body, such as bilirubin and steroid 
hormones (56). Numerous studies (57, 58) have shown that there is a 
relationship between the MFO system and AA in which increased drug 
metabolism decreases levels of AA and also decreased levels of AA hinders the 
drug metabolizing ability of MFO; however, there is no direct evidence for the 
site of action of AA. Ascorbic acid is also involved in cholesterol metabolism 
occurring within the MFO system although its site of action is again unknown. 
Studies suggest that a vitamin C deficiency in guinea pigs leads to a reduction 
in cholesterol metabolism (59).
Other functions of AA include facilitation of iron absorption (60), association 
with synthesis of prostaglandins, and involvement in the functioning of the 
immune system (61). Ascorbic add may play an important role in a redox 
system involving NADH-free radical reductase, which functions in membrane 
energetics and in the regulation of cell growth, and is found in cell membranes 
and organelle membranes (62).
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IV. Ascorbic Acid Metabolism in Diabetes
Ascorbic acid metabolism is abnormal in diabetic humans and animals, but 
disagreement exists as to how it is altered. For example, several studies have 
shown that plasma levels of AA in diabetic patients are significantly decreased 
while DHAA levels are increased (63, 64, 65). Other studies found normal 
DHAA levels in the plasma of diabetic patients (66, 67). Despite their ability to 
synthesize AA, decreased levels of AA are reported in various tissues of rats 
that were made diabetic with alloxan (68). Few studies have determined tissue 
levels of DHAA in diabetic animals but at least one attempt was made to 
measure levels of both AA and DHAA in the plasma, liver, testes, and kidneys of 
diabetic and non-diabetic rats (69). In this case an increase in DHAA levels was 
found only in the plasma; however, levels of AA were significantly decreased in 
all tissues except testes.
The mechanism by which the decrease in AA in diabetic animals occurs is 
not well understood. Mann (70) noted the structural similarity between L-AA 
and D-glucose and suggested that both may be involved in the same membrane 
transport system. He formulated two hypotheses to explain the decrease of AA 
that occurs in hyperglycemia (71). First, he proposed that the transport of AA 
across the cell membrane is hindered by glucose. Assuming they share a 
common transport mechanism, hyperglycemia would saturate the carrier with 
glucose. His second hypothesis was that the transport of AA in certain tissues is 
accelerated by insulin. In the absence of insulin a decrease in transport of 
vitamin C would occur. Later, Mann (72) showed that D-glucose inhibited the 
transport of DHAA into human red-blood cells, which are non-insulin dependent 
tissues. Other researchers observe inhibition of AA transport with glucose in 
human lymphocytes (73) and human cardiac endothelial cells (74) and 
concluded that glucose and AA share a common transporter (75).
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It is also suggested that there may be a decreased number of glucose 
transporters in the plasma membrane of diabetic leukocytes, and since AA and 
glucose share the same transporter, this can explain the decrease in AA 
observed in diabetic tissues. This conclusion was deduced from studies (68) in 
which the rate of DHAA uptake by blood granulocytes and mononuclear cells 
was slower and the plasma concentrations of AA lower, among persons with 
diabetes mellitus. Vmax transport rates for DHAA, 2-deoxyglucose and 3-o- 
methylglucose were decreased each to the same degree in diabetic cells but 
Km values were not different from those observed in non-diabetic cells.
Dehyroascorbic acid is structurally similar to alloxan, a compound used 
experimentally to induce diabetes. It is known to be toxic and daily intravenous 
injections of DHAA into rats at a dose of 20 mg/kg was found to result in lasting 
hyperglycemia after 3 weeks (76, 77). A third study confirmed this effect and 
attributed it to damage sustained by the beta cells of the pancreas (78).
The disturbance of AA metabolism in diabetes is of interest because it may 
be an important factor in the pathogenesis of many diabetic complications (74, 
79, 80, 81), such as cataract, keratopathy, retinopathy, neuropathy, 
microangiopathy, and nephropathy. In one study (82), it was found that 
diabetic subjects had low plasma ascorbate levels but those with retinopathy 
had significantly lower plasma ascorbate status compared to diabetic subjects 
who did not have vascular complications.
Mann and Newton (72) proposed that a decrease in AA levels in tissues of 
diabetic patients would lead to the development of a "local scurvy" due to 
impaired transport. The resulting lesion would not be the same as classical 
scurvy since the deficit is in a local AA supply rather than an extracellular 
supply. Ascorbic acid is also important in regulating the intracellular redox state 
and scavenging reactive free radicals. Therefore, AA deficiency may lead to
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increased susceptibility to oxidative damage in diabetic subjects. Ascorbic acid 
deficiencies may also be responsible for some of the collagen abnormalities in 
diabetes, such as decreased capillary integrity and poor wound healing. In 
addition, both DHAA and 2,3-diketogulonic acid, oxidation products of AA, are 
known to initiate cross-linking of lens proteins (83, 84, 85).
The sorbitol or polyol pathway is implicated as a source of disturbances that 
lead to various complications of diabetes (86, 87), including cataracts, 
neuropathy, retinopathy, and nephropathy. The sorbitol pathway involves the 
reduction of D-glucose to sorbitol catalyzed by aldose reductase and the 
oxidation of sorbitol to fructose by sorbitol dehydrogenase. Normally the flux of 
glucose through the sorbitol pathway is very low but it can be increased and 
has been reported to account for 1/3 of the glucose metabolism in rabbit lens at 
high glucose concentrations (86). A consequence of hyperglycemia in diabetes 
is increased metabolism of glucose by the polyol pathway. Sorbitol is not 
permeable to cell membranes and tends to accumulate in the cell. There is no 
known physiological role for sorbitol. Levels are negligible in most tissues but 
under hyperglycemic conditions, the accumulation of sorbitol in tissues is 
increased. Accumulation of sorbitol is found in diabetic tissues in proportion to 
the concentration of extracellular glucose in sensitive tissues (87). Aldose 
reductase inhibitors prevent the buildup of sorbitol, which is thought to decrease 
the propensity for diabetic complications. The interaction between AA and the 
sorbitol pathway is not well understood, but AA supplemented patients are 
found to have reduced erythrocyte sorbitol accumulation by 27-56% depending 
upon the dosage of AA given (79). Other studies have shown that low plasma 
AA levels in diabetic rats could be normalized by dietary AA supplement and 
also by the aldose reductase inhibitor, tolrestat.(80).
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v. Measurement of AA and DHAA
Since AA was first discovered to be the antiscorbutic factor vital to our diets, 
researchers were interested in determining the basic biochemistry of the 
vitamin, its content in foods, and tissue concentrations associated with disease. 
Attainment of this knowledge required the development of assays to measure 
levels of the vitamin in various substances. Earlier developed assays were 
non-specific and not satisfactory for detailed work. Most assays involving 
measurement of AA and DHAA take advantage their potential to function in a 
redox system.
Methods developed include fluorometric, spectrophotometric, 
chromatographic, and colorimetric assays. One of the earliest (88) and most 
frequently used methods involves the ability of AA to reduce and subsequently 
decolorize the indicator, 2,6-dichlorophenol indophenol. A limitation of this 
method is its nonspecificity in that other reducing agents are able to decolorize 
the indicator. Another colorimetric assay developed involves the ability of 
DHAA to react with 2,4-dinitrophenylhydrazine to form an osazone and then 
conversion of osazone to furfural which can be colorimetrically detected (89). 
However, this method is also nonspecific because others compounds in the 
samples are capable of reacting to form osazones.
Spectrophotometric methods are also used and involve direct detection 
where ultraviolet light absorption of AA (265 nm) and of DHAA (230-280 nm) is 
followed. These assays have a limited value because of interference by many 
other biological substances absorbing in this region.
Chromatographic methods hold the most promise for specific methods in the 
detection of AA, DHAA, and 2,3-DKG. A method involving paper 
chromatography was developed to measure AA and various breakdown 
products (90). However, high-pressure liquid chromatography (HPLC) has
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proven to be a powerful and efficient technique for the separation, identification, 
and quantitation of small quantities of AA and its metabolites. Combining HPLC 
with other methods allows an assay, that was nonspecific before the addition of 
HPLC, to become specific because the separation of the compound of interest 
from other constituents of the sample can be achieved. Numerous procedures 
using HPLC were developed to measure AA in foods and tissues (91, 92, 93). 
Variations in the procedures include the column type, mobile phase, detection 
system, and stabilization of samples.
Ascorbic acid is subject to oxidation in biological solutions and is therefore 
unstable. The first oxidation product, DHAA, Is extremely unstable and reactive. 
It is rapidly hydrolyzed irreversibly to DKG with a half life of six minutes at a 
temperature of 37° C and pH 7.0 (94). Metaphosphoric acid (MPA) and 
trichloroacetic acid (TCA) are the reagents of choice for stabilizing AA and 
DHAA acting by precipitating proteins and maintaining a reduced pH in the 
sample (95). Long term stability of AA in acidic medium has been reported 
from 30 days at -20°C (96) to 5 weeks at -70°C (97).
Detection methods used with HPLC include ultraviolet (98, 99, 100), 
radiochemical (101), fluorometric (102), and electrochemical analysis (103,
104, 105). These methods all require stabilization of the sample and vary in 
sensitivity. One method to analyze AA and DHAA involves derivatization with 
o-phenylenediamine to separate DHAA from AA (106). The AA contained in 
the sample is measured electrochemically and the DHAA is measured by UV 
analysis. The use of HPLC and electrochemical (EC) detection in the analysis 
of AA has been applied to food and animal tissues with excellent success, 
whereas the application of HPLC-EC to the measurement of DHAA in a variety 
of tissues has not been as successful, mainly due to the instability of the 
molecule. However, electrochemical detection of AA and DHAA in the samples
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offers many advantages. It requires small injection volumes, has increased 
selectivity for AA, and is capable of low detection limits.
There are two types of EC detection, amperometric and coulometric. 
Theoretically, all EC detectors are amperometric, meaning the potential applied 
to the detecting electrode is held constant while the resulting currents are 
monitored as analytes flow past the detector. Most amperometric sensors 
cause approximately 1-5% of the passing analyte to undergo charge transfer. 
However, coulometric electrochemical detection utilizes porous, flow-through 
electrodes. An oxidation reaction takes place at the surface of the electrodes 
and the charge that is transferred is measured. In this way, the electrode reacts 
with 100% of the analyte, resulting in increased sensitivity.
Detection of AA by electrochemical detection offers the advantage of 
increased selectivity for AA. This is accomplished by placement of the 
electrodes in series, where the first electrode reacts with and eliminates 
contaminating compounds so they will not interfere at the second electrode, 
where oxidation of AA occurs and is detected. Dehydroascorbic acid is not 
electrochemically active and so it must be measured indirectly. The procedure 
involves the measurement of total AA (DHAA + AA). Ascorbic acid is measured 
first, DHAA is then reduced to AA in the sample, and then subsequent 
measurement of total AA can occur. The challenge in measuring DHAA in 
biological samples is its extreme instability. Success in measuring DHAA with 
electrochemical detection has almost exclusively occurred in biological fluids 
including plasma (97, 98, 107, 108, 109), protein free human milk (107), 
cerebrospinal fluid (109), and leukocyte extracts (107) rather than in whole 
tissues.
STATEMENT OF THE PROBLEM
The purpose of the present study was two-fold. The first purpose was to 
develop a sensitive and reliable method for accurately measuring ascorbic acid 
(AA) and dehydroascorbic acid (DHAA) in mammalian tissues. The challenge 
in accomplishing this goal is the instability of DHAA. The verification of a 
reliable assay requires the assay's ability to linearly recover exogenous DHAA 
and AA added to tissue homogenates. The second objective was to apply the 
method to the measurement of AA and DHAA in normal and diabetic tissues.
MATERIALS AND METHODS
I. Experimental Animals
Male Spraque-Dawley rats, obtained from Bio-Labs Corporation (St. Paul, 
MN), were used for this study. The number of animals used in the determination 
of AA and DHAA in normal and diabetic tissues was 23; the number used in the 
initial development of the method was undetermined since tissues were 
donated by another research group using the same strain of rats.
The animals were kept at the Animal Resource Facility (UND Medical 
School, Grand Forks, ND). Environment conditions were maintained at a 
temperature of 72°F and a 12 hour/12 hour light/dark cycle. Animals were kept 
in stainless steel, mesh floor cages with an area of 160.9 in2. Two animals 
were housed in each cage. The only time the animals were removed from this 
environment was for tissue analysis. Rats were maintained ad libitum on Purina 
Rodent Lab Chow 5001 and water.
II. instrumentation for Analysis
A) High-Pressure Liquid Chromatography (HPLC) System
The equipment used for analysis consisted of a Beckman System Gold 
HPLC containing two Beckman Model 11 OB high pressure pumps, a System 
Gold 502 autosampler with a 20 pi injection loop, and a Waters Radial 
Compression Separation System consisting of a radial compression module 
model RCM-100 with a Waters Radial-Pak cartridge, Resolve C i8 reverse- 
phase column. Data was collected with the assistance of a System Gold
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Analog Interface Module 406 and an IBM model 55 SX personal computer. The 
computer was used to integrate and interpret the resulting chromatogram, with 
the aid of System Gold software. Results were printed on an Epson FX-850 
printer and data were stored on floppy diskettes. The samples were injected 
onto the column and AA was eluted with a mobile phase consisting of 0.2 M 
KH2P0 4 ( pH 3.0, filtered through 0.22 pm filters (Miilipore Corp., Bedford, MA) 
prior to its use. The flow rate was maintained at 1 ml min'1. The system was 
cleaned periodically with 10% methanol and then equilibrated with the mobile 
phase prior to use.
B) £ifigtEQchjemicaiJpgtggtQ.r. System
1) Instrumentation
The content of AA in the samples was quantified by means of an ESA Model 
5100A Coulochem Multi-Electrode Electrochemical Detector (ESA, Inc.,
Bedford, MA) containing an ESA Mode! 5010 Analytical Cell. In-line high 
pressure carbon filters (ESA, Inc.) were placed between the analytical column 
and the electrodes.
2) Initialization,.of .Electrochemical Detector for AA Analysis
The appropriate detector settings for optimal AA sensitivity and selectivity 
were determined by making a current-voltage (C-V) curve, which is a graph of 
response (current) versus potential (voltage). By reviewing the C-V curve, the 
optimal voltage was selected for both electrodes so a maximum response was 
obtained while minimizing background noise from interfering compounds.
The procedure for making a C-V curve begins with the preparation of 
samples containing the analyte of interest, AA. Since DHAA is not 
electrochemically active, the developed method involved detection of 
endogenous AA and total AA. Total AA included endogenous AA and 
endogenous DHAA that was reduced to AA. A 1 mM solution of AA was
prepared in double glass distilled water and kept on ice until analysis. The 
model 5010 Analytical Cell contains two coulometrically efficient porous 
graphite working electrodes placed in series. In preparing the C-V curve, 
detector 1 is set at a very low potential (-0.5 V) because the optimal potential for 
detector 2 needed to be determined. The potential at the detector 2 w'as varied 
with each injection. To begin the determinations, detector 2 was set at -0.4 V, 
the AA solution was injected and the response was recorded. For the next 
injection, the potential at detector 2 was increased by 0.05 V to -0.35 V, the 
sample injected, and the response recorded. This procedure was repeated 
until the response had reached its maximum, i.e., there was no change in 
response (peak height) for increases in potential.
III. Experimental Compounds
A) Mobile Phase
The mobile phase consisted of 0.20 M KH2PO4 that was brought to a pH of 
3.0 with KOH. The final solution was filtered through a 0.22 jim filter (Millipore) 
before its use. Monobasic potassium phosphate and 85% ortho-phosphoric 
acid were purchased from Fischer Scientific and were HPLC grade. Potassium 
hydroxide (45%) was prepared from a stock of KOH pellets purchased from 
Fisher Scientific and was A.C.S. grade.
B) Buff8L
The buffer used in the analysis of DHAA consisted of 120 mM dibasic 
sodium phosphate brought to a pH of 7.2 with 120 mM monobasic sodium 
phosphate. The buffer also contained 0.1 mM EDTA and 1 mM thiourea for 
stabilization of AA and DHAA. Dibasic sodium phosphate was purchased from 
Fischer Scientific and its quality was enzyme grade. Monobasic sodium 
phosphate was purchased from Matheson, Coleman and Bell and was A.C.S.
grade. The EDTA was purchased from Sigma and was Sigma grade. The 
buffer was also filtered through a 0.22 jim filter (Millipore Corp. ) before use.
C) Mela-Phosphoric Acid
Two solutions of meta-phosphoric acid were used in the assay. For initial 
stabilization and homogenization of the tissue sample, a 0.3% solution was 
used containing 1 mM thiourea (Sigma), and 0.1 mM EDTA (Sigma). The 
second solution was a 10% meta-phosphoric solution also containing 0.1 mM 
EDTA and 1 mM thiourea and was used for the reaction involved in the analysis 
of AA and the termination of the reducing reaction for measurement of total AA. 
The solutions were made by dissolving meta-phosphoric acid in double glass 
distilled water. The meta-phosphoric acid was purchased from Fisher Scientific 
and was A.C.S grade.
D) B-Mercaptoethanol
The reducing agent, p-mercaptoethanol, or 2-mercaptoethanol, used in the 
analysis was purchased from Sigma Chemical Co. (St. Louis, Mo.).
IV. Procedure for Analysis
A) Obtaining the Tissue samples
Tissues were obtained from rats four weeks after injection with 
streptozotocin or vehicle. After anesthetization of the rats with ether, various 
tissues were surgically removed. Blood was either removed through a heart 
puncture or the common iliac artery, which was the technique of euthanizing the 
animals. The tissues were weighed and immediately placed in 3 mis of 0.3% 
meta-phosphoric acid, 0.1 mM EDTA, and 1 mM thiourea per gram of tissue to 
stabilize the analytes of interest.
B) Analysis of Compounds
1) Ascorbic Acid
Samples were placed in meta-phosphoric acid and homogenized using 
tissue grinders purchased from Curtin Matheson Scientific, Inc. (Eden Prairie, 
MN). The homogenates were centrifuged at 19,000g for 20 minutes. One 
hundred pi of the supernatant were removed and used for AA analysis. Nine 
hundred pi of 10% meta-phosphoric acid were added to the sample to stabilize 
and allow for analysis by HPLC.
2) Dehvdroascorbic Acid
Total AA analysis included endogenous AA and endogenous DHAA that 
was reduced to AA. By subtracting the endogenous AA, determined in the 
previously mentioned assay, from the total AA, the endogenous DHAA could be 
quantified. One hundred pi of the supernatant were removed from the 
homogenized sample that was centrifuged as for the AA determination. The 
reducing agent, [3-mercaptoethanol, was added to the sample to a final 
concentration of 10 mM in 390 pi of sodium phosphate buffer (pH 7.2). This 
solution was allowed to react for 10 minutes at room temperature and the 
reaction was stopped with the addition of an equal volume of 10% meta- 
phosphoric acid.
3) Sample Analysis using HPLC-EC System
The samples that were analyzed were either analyzed immediately or frozen 
for later analysis. The data generated from an individual sample were obtained 
in the form of a chromatogram in which the AA peak was identified and peak 
area integrated. Unknowns were compared to standard peaks of known AA 
concentration, to yield a concentration of AA in the sample.
The standards were made at the time of analysis. They were prepared by 
making solutions of different concentrations of AA in 5% meta-phosphoric acid
and injecting them into the HPLC-EC system. A computer progam called 
System Gold version 510 was used to integrate peak areas.
v. Determination..of ApprQpilate-A&sgy Conditions.
A) Stability..Qf-the.ErosenJSamplfi
Liver homogenates were used to determine the stability of prepared 
samples ready for analysis but frozen for various lengths of time before 
analysis. The samples were acidic since all contained meta-phosphoric acid.
B) Assay Conditions
The determination of appropriate assay conditions for the reduction of DHAA 
was accomplished by varying one of the conditions while holding the others 
constant. The optimal condition was chosen on the basis of percent conversion 
of DHAA to AA of an exogenously added amount of DHAA in the samples. Liver 
samples were used for the determinations of optimal conditions. The 
exogenous DHAA that was added was from a solution of AA which was 
oxidized to DHAA by bromination. The bromine was removed by blowing a 
stream of N2 over the solution. The conditions that were varied were reaction 
temperature, reducing agent concentration, reaction time and buffer pH.
C) Recoveries
In the determination of optimal reaction conditions, exogenous AA and 
DHAA were recovered in a linear fashion from tissue homogenates. Recoveries 
of exogenous DHAA and AA added to tissue samples and buffer were used for 
verification that the assay was working. Ten pi of 10 mM AA was added to 100 
pi of tissue homogenates, analyzed for AA in diabetic studies and addition of 
890 pi of 10% MPA followed . Ten pi of 10 mM DHAA was added to 100 pi of
tissue homogenates, prepared from diabetic and nondiabetic animals followed 
by addition of 380 pi of sodium phosphate buffer and 10 pi of (3-
mercaptoethanol. The reaction was stopped with 500 pi of 10% MPA followed. 
The exogenous AA and DHAA were also recovered from buffer in these studies 
to evaluate the actual amount of AA and DHAA added to tissues.
VL Diabetic Studies
A) Streptozotocin Administration
Thirteen rats, 180 to 200 gram body weight, were made diabetic with a 
single intraperitoneal injection of 75 mg streptozotocin (Sigma Chemical Co.) 
per kg body weight. The streptozotocin solution was dissolved in 10 mM citrate 
buffer with a pH of 4.5. Ten control rats received an intraperitoneal injection of 
10 mM citrate buffer, pH 4.5.
B) Blood Glucose Measurements
in diabetic studies, blood glucose was measured to verify a diabetic state. 
The GOD-Perid (Sigma) procedure, based on the oxidation of chromagen by a 
coupled reaction involving glucose oxidase and peroxidase, was used to 
establish blood glucose levels. Two-tenths of a ml of whole blood were placed 
in 0.8 mis cold water. This ml of sample was added to 1.0 ml of 8% 
Ba(OH)28H20. After 1 minute 1.0 ml of 2% ZnSO47H20 was added and the 
mixture was vortexed. The precipitated protein was removed by centrifugation 
at 1850 rpm for 15 minutes in a table top centrifuge at room temperature. One- 
half ml of the resulting supernate was removed as samples from control animals 
and as samples from diabetic animals, 0.1 ml of supernate was diluted with 0.4 
ml of water and analyzed for glucose concentration.
Two ml of the GOD-Perid reagent was added to the above test tubes and 
the reaction was allowed to go to completion in 25 minutes at room temperature 
and absorbance was determined at 505 nm. The assay contained a calibration 
blank and 4 standards containing 0.005, 0.01, 0.03, and 0.05 mg glucose.
20
Using the values obtained from the standards and the appropriate dilution 
factors, the concentration of glucose was calculated.
VH. Statistical Analysis
Data analysis included analysis of variance and linear regression.
The accepted level of significance for F0bs was a<0.05. Linear regression was 
used to produce standard curves for the recovery of exogenous AA and DHAA 
from buffer and tissues. Multivariate ANOVAS were performed to compare the 
conditions tested in the assays involving the determinations of optimal pH, 
reaction time, reaction temperature, and reducing agent concentration. 
Univariate ANOVAS were performed to compare the AA and DHAA 




The results for the C-V (current to voltage) cl:, ve for AA are presented in 
figure 3. Observations that can be made from this curve and the determination 
of optimal potentials for both detectors are as follows. E0' is the formal potential 
for AA. At potentials negative to E0' little or no oxidation of AA occurs. At 
potentials positive to E0' the current quickly reaches its limiting value and the 
half-wave potential, E1/2 is equivalent to the formal potential. The half wave 
potential is defined as that potential at which current equals one-half of the 
limiting value. Detector 1 is set at the foot of the C-V curve for the analyte of 
interest. This is done to decrease background currents and prevent unwanted 
peaks that result from eluants that oxidize at lower potentials than the analyte of 
interest. The potential of detector 2 is set at the plateau of the C-V curve, where 
maximum response is observed for the analyte of interest. The detector 
potentials for optimal AA measurement were determined to be - 0.3 V for 
detector 1 and 0.0 V for detector 2.
II. S tab ility  of Frozen Samples
Samples of liver homogenates were prepared for analysis of total AA (AA + 
DHAA) and were frozen before HPLC-EC analysis. Samples were removed 
from the freezer at various lengths of time after initial freezing and total AA was 
measured. These values were then compared to initial total before freezing AA 
concentration.
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The results are graphed in figure 4 and indicate that there is no significant loss
of total AA in the sample in a time period up to 55 days.
\
Hi. Conditions_f.Qf_Reducinq.PHAA to AA
The results for the determination of appropriate buffer pH, reaction time, 
reaction temperature, and reducing agent concentration for the reduction of 
DHAA to AA in tissue homogenates are presented in figures 5,6, 7, and 8. The 
optimal conditions were selected by determining the maximum conversion of 
exogenous DHAA to AA added to the reaction mixture. The process of making 
DHAA through bromination of AA results in a loss of approximately 20% of the 
original AA. In order to obtain actual values of AA, DHAA, and DKG in 
commercial samples of AA and in DHAA solutions obtained from AA by 
bromination, 14C radiolabelled AA was used. The radioactive AA is separated 
by HPLC, where the degradation products of AA, DHAA and DKG, along with 
AA are separated. The fractions are collected and the concentration of these 
products is determined by counting the radiolabelled components by liquid 
scintillation spectometry. The results presented in table 1 indicate that the 
commercial radiolabelled AA is about 75% AA and 16% DHAA, therefore the 
total AA (DHAA + AA) in the original sample is 91%. About 69% of the original 
total AA results in DHAA after bromination with the remainder degrading to 
DKG. Therefore, a 22% loss of DHAA is expected with bromination, so a 78% 
or greater recovery of exogenous DHAA would be 100% of what is present.
Data are presented in this manner for the determination of optimal conditions.
In figure 5, the appropriate buffer pH was determined for recovery of DHAA 
from a sodium phosphate buffer. Based on previous reports (110), three pH's 
6.2, 7.2, and 8.2 were used for screening. It was determined that the recover/ of 
DHAA at pH 8.2 was significantly less than the recovery at pH 6.2 and pH 7.2.
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Although greater recovery was not statistically significant at a pH of 7.2 it was 
chosen as the buffer pH for the assay.
In figure 6, the results are presented for the determination of the optimal 
reaction time for the reducing reaction. The conversion of DHAA to AA at times 
2, 5, 10, and 20 minutes were all significantly different than conversion at time 
zero and two minutes. The reaction time chosen for the assay was 10 minutes.
Figure 7 shows the results from experiments in which optimal reaction 
temperature are shown. There was no significant difference in conversion of 
exogenous DHAA to AA added to liver homogenates when the reaction was 
carried out at room temperature or in ice. For convenience, room temperature 
was chosen as the reaction temperature for the assay.
In figure 8, the results are presented for the determination of the optimal 
concentration of reducing agent, (3-mercaptoethanol. A concentration of 1 mM 
was not as effective as 5, 10, or 20 mM. The (3-mercaptoethanol concentration 
for maximum conversion of DHAA to AA was chosen as 10 mM. From the data 
presented in figures 5, 6, 7, and 8, the conditions for reducing DHAA to AA in 
liver homogenates are: a buffer pH of 7.2, a reaction time of 10 minutes, a 
reaction temperature at room temperature, and a 10 mM concentration of (3- 
mercaptoethanol.
IV. Standard Curves of Recoveries
Figures 9, 10, and 11 are the results obtained from liver, brain, and kidney 
homogenates, respectively, in which varying amounts of AA were added and 
recovered. These figures indicate that AA was recovered in a linear fashion 
from all homogenates.
Figures 12, 13, 14, and 15, are standard curves obtained from buffer, liver, 
brain, and kidney homogenates, respectively, in which DHAA was added to the
homogenates and recovered in a linear fashion using the reducing reaction 
explained in the methods section.
The standard curves obtained for the recoveries of both AA and DHAA in 
tissue homogenates indicates that stabilization and measurement of the 
analytes is satisfactory and the method described is capable of accurately 
measuring endogenous ievels of AA and DHAA.
v.
Once the optimal conditions for reducing DHAA to AA were established and 
recoveries of AA and DHAA were verified, the method was applied to 
measurement of endogenous levels of AA and DHAA in diabetic rats. Table 2 
contains blood glucose measurements from diabetic and control rats used in 
the study. Diabetic animals had significantly greater blood glucose 
concentrations as compared to control animals. This measurement is used to 
confirm that animals were in a uncontrolled diabetic state.
Figure 16 shows results of endogenous AA measurements in liver, kidney 
and brain tissues from diabetic and control animals. Diabetic liver and kidney 
tissues had significantly decreased levels of AA compared to control tissues. 
There was no significant difference of AA levels in diabetic and control brain 
tissues.
Figure 17 shows the results of endogenous DHAA measurements in liver, 
kidney, and brain tissues from diabetic and control animals. Levels of DHAA in 
diabetic liver and kidney were significantly increased compared to control liver 
and kidney tissues. There was no DHAA detected in the nondiabetic livers. 
There was no significant difference in the levels of DHAA measured in diabetic 
and control brain tissues.
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In figure 18 (A & B) the results for the levels of AA and DHAA measured in 
diabetic and control adrenal glands are shewn. There was no significant 
difference in AA levels between diabetic and control adrenal glands. DHAA in 
diabetic adrenal glands was significantly increased compared to levels found in 
control adrenals, in which DHAA was not detectable.
Recoveries of exogenous AA and DHAA added to diabetic and control brain, 
kidney, and liver tissues were done to verify that the assay was working.
Results are presented in figure 19 . Recoveries of AA and DHAA from both 
diabetic and nondiabetic tissues were greater than 90%.
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DISCUSSION
Ascorbic acid has many important functions and is essential for the 
maintenance of health. Since AA and DHAA levels in various tissues of healthy 
subjects are maintained at very low levels, accurate detection of these 
compounds is required. DHAA and AA are unstable and reactive compounds 
making their measurement difficult, especially in tissues which contain 
substances capable of reacting with AA and DHAA and therefore increasing 
their instability. A highly sensitive, selective, and reliable method for measuring 
DHAA in tissues has not so far been reported in the literature.
Methods for measuring AA and DHAA have improved with the advent of 
HPLC combined with electrochemical (EC) detection. HPLC allows for 
increased selectivity and EC detection utilizes the unique redox properties of 
AA. Coulometric electrochemical detection increases the sensitivity of the 
assay by completely oxidizing the analyte at the electrode's surface. The 
detectors are set at potentials that are optimal for the oxidation of AA and thus, 
for its determination. Assays for determining DHAA using HPLC-EC include 
biological fluids, such as cerebrospinal fluid (109), plasma (97, 98, 107, 108, 
109) human milk (107), and leukocyte extracts (107). These methods are 
reliable for these fluid measurements but have not been extensively applied to 
tissue samples. One method (98) involves derivatization of DHAA with 2,4- 
diphenylhydrazine so that simultaneous measurement of AA by EC detection 
and DHAA by ultraviolet detection is possible. However, low detection limits of 
DHAA are not possible with this method, and therefore it is not satisfactory for
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determining differences in animal tissues that normally have very low levels of 
DHAA. At least one group developed a method (108) which measures both AA 
and DHAA in tissues, in addition to biological fluids, and foods. In this assay, 
homocysteine is the reducing agent. The reaction converts endogenous DHAA 
to AA, over a period of 30 minutes at room termperature and at a pH of 7.1, for 
electrochemical measurement. The detection limits for this assay are 
suggested to be 50 pg/20 pi injection volume, while the presently developed 
method has detection limits of 2 pg/20 pi injection volume. The instability of 
DHAA and AA is not appropriately addressed in their procedure. The reduction 
of DHAA for 30 minutes at room temperature and pH 7.1 appears to be 
inappropriate considering the half-life of DHAA is 6 minutes at a pH of 7.0 and a 
temperature of 37°C (94).
Ascorbic acid is involved in a variety of functions in the body. It functions in 
collagen formation (34, 35, 36), acquirement of energy for muscle tissues (34, 
35, 37), synthesis of neurotransmitters and neurohormones (48-55), protection 
against reactive and potentially damaging free radicals (39-47), and the 
immune response (61). It is understandable then, that a deficiency of this 
vitamin could produce some damaging effects. The symptoms of scurvy occur 
when the deficiency is taken to its full extent, it is possible that there is an 
intermediate level of deficiency that could produce clinical symptoms not exactly 
similar to those seen in scurvy (72). The present study has shown that in 
diabetic animals, there is a decrease in concentrations of AA and an increase in 
DHAA in some tissues.
AA concentrations were decreased in diabetic liver and kidney but no 
decrease was found in brain or adrenal tissues (Fig. 17 & 19). The mechanisms 
for the decreased concentrations observed in diabetes are unclear. Mann (71) 
proposed that there is competition for the transporter by glucose and DHAA .
This then could be a possible explanation for decreased levels of AA since 
hyperglycemia is associated with diabetes. The high glucose levels could more 
effectively compete for available transport mechanisms. One problem with this 
explanation is that a decreased concentration of AA was not observed in all the 
tissues. Low concentrations of AA in diabetes could be associated with its high 
metabolic turnover, resulting in increased consumption of AA by oxidation to 
DHAA (64). This could explain low concentrations of AA found in diabetic 
human tissues, in which intake of AA may not be adequate due to the rapid 
turnover. In the present study, rats, which are capable of synthesizing ascorbic 
acid, were evaluated. In this case, a decreased production of AA, one that is not 
capable of meeting its rapid turnover, maybe a possible explanation for 
decreased tissue levels of AA.
DHAA concentrations were increased in liver, adrenals, and kidney tissues 
but not in brain tissues of diabetic rats (Fig. 18 &19). There are a few 
possibilities to explain this occurrence. For example, an increased degradation 
of AA from its rapid turnover in diabetic subjects could lead to increases in its 
oxidized product, DHAA. There also could be an insufficiency in the 
mechanisms that regenerate ascorbic acid from its oxidized products. For 
example, reduction of glutathione levels in various tissues (111, 112) may 
reduce the potential for nonenzymatic mechanisms to appropriately regenerate 
ascorbate. Therefore, utilization of AA by its involvement in various biochemical 
reactions could lead to a buildup of DHAA because at least one mechanisms for 
regenerating AA is inadequate. Some tissues prefer DHAA as the form for 
uptake. When DHAA is taken up by these tissues, it appears in the cell as AA 
(113). Although the mechanism is unclear, it is possible that these tissues have 
reducing mechanisms (i.e. proteins) in close proximity to the transporter that are 
not optimally functioning. This would result in a decrease in tissue AA
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concentrations because of the tissue's inability to transport this form into the 
tissue; and DHAA concentrations would be increased because of the tissue's 
preference for uptake of DHAA and the subsequent decreased ability for DHAA 
to be reduced.
It is known that in diabetes giycosylation of proteins occur that can reduce or 
inhibit their activities (114,115). Altered AA metabolism in diabetics could result 
from decreased function, due to giycosylation, of AA or DHAA transport proteins 
or enzymes involved in keeping AA in its reduced form.
Altered AA metabolism in certain tissues could account for some of the 
complications associated with diabetes. Decreased levels of AA may lead to an 
accumulation of sorbitol since AA plays a role in inhibiting the sorbitol pathway. 
AA inhibits this pathway either by competing for glucose entrance into this 
pathway and thereby keeping the reaction products low, or by inhibiting the 
enzymes responsible for this conversion of glucose to sorbitol. Sorbitol may be 
a contributor in many of the diabetic complications (86, 87). Increased levels of 
DHAA could also account for some of the diabetic complications. It is known to 
be involved in giycosylation reactions and increased concentrations would 
therefore be expected to increase these types of reactions (83, 84, 85). DHAA 
does not retain the antioxidant capabilities that AA has which could be 
associated with increased cell damage (116) . DHAA is also known to be toxic 
to cell membranes (78). Studies have shown that diabetic patients with 
complications, such as retinopathy, had lower plasma AA concentrations that 
diabetic patients without complications (82).
It is interesting to speculate as to why brain tissue did not have altered levels 
of AA and DHAA in diabetic compared to nondiabetic tissues. It may be that AA 
is critical to the nervous system and is therefore, conserved. It is also possible 
that whatever mechanisms account for the inappropriate metabolism of AA in
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other tissues are not involved in the brain. The fact that vitamin C is such an 
important component in many biochemical reactions and that its metabolism in 
diabetes is altered renders it an important part of the diabetic syndrome and 




A reliable method for measuring AA and DHAA was established. Its 
reliability has been verified by recoveries of exogenous AA and DHAA in 
mammalian tissues. Optimal conditions for reducing DHAA in tissue samples 
were determined to be: a buffer pH of 7.2, a reaction time of 10 minutes, a 
reaction temperature at room temperature, and a 10 mM concentration of (3- 
mercaptoethanol.
AA and DHAA were measured in diabetic and nondiabetic rat tissues using 
this method and the following results were obtained:
1. AA in the kidney of diabetic rats was 1/2 that of nondiabetic kidney. 
DHAA in the diabetic kidney was 7 times more than nondiabetic 
concentrations.
2. AA in diabetic liver was 1/2 that of nondiabetic liver. DHAA was 136 
nmol/gram in diabetic liver and was not detectable in the nondiabetic 
liver.
3. AA and DHAA concentrations in diabetic rat brain tissues were not 
significantly different from the levels found in nondiabetic brain tissues.
4. AA concentrations in diabetic adrenal glands was not different from 
nondiabetic concentrations. DHAA in the diabetic adrenai glands was 







Composition of Radiolabeled AA and Prepared DHAA Solutions
Solution n %AA %DHAA %DKG
AA Standard j * r ~i v> 74.9+1.2 16.2 ±1.0 8.9 ±0.8
DHAA Standard 37 1.8 ±0.5 69.2 ± 2.7 29.1 ±2.9
DHAA was prepared by brominating a solution of AA and blowing off the excess bromine 
with a stream of N2.





Diabetic Rats 1 0 2 1 . 2 1  r 1.085
Control Rats 1 0 6.504 0.311
*p =0.001
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FIGURE 2. Metabolism of Ascorbic Acid
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FIGURE 3. C-V Curve for Ascorbic Acid Curve was made using a 1 mM 
ascorbic acid solution. Detector one (D-i) was set at -0.4 V while the 



















FIGURE 4. Stability of Frozen Samples of a Liver Homogenate
Samples were frozen after the reduction reaction (to measure total 
AA) was completed by the addition of metaphosphoric acid. 
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FIGURE 5. Determination of Optimal Buffer pH The pH for a 120 mM
sodium phosphate buffer used for the reducing reaction of DHAA to 
AA in liver homogenates. Percent conversion of 1 mM DHAA to AA 
added to liver homogenates in buffers of pH 6.2, 7.2, and 8.2 was 
determined.







FIGURE 6. Determination of the Optimal Reaction Time The optima!
reaction time for the reducing reaction was evaluated by adding 1 mM 
DHAA to liver homogenates and determining the conversion of DHAA 
to AA when the reducing reaction was carried out at 0, 2, 5 10, and 20 
minutes.
* p < 0.05 for time 0 minutes compared to 2, 5, 10, and 20 minutes 


















FIGURE 7. Determination of Optimal Reaction Temperature The
optimal reaction temperature for the reducing reaction involved in 
measuring total AA was evaluated by adding DHAA to liver 
homogenates. Conversion of the exogenous DHAA was determined 
in homogenates in which the reducing reaction was carried out at 











FIGURE 8. Determination of Optimal Reducing Agent
Concentration The optimal concentration of the reducing agent 
concentration, (3-mercaptoethanol, was evaluated in liver 
homogenates. One mM DHAA was added to liver homogenates 
which then was reduced to measure total AA. Percent conversion of 
DHAA in homogenates using 1,5, 10, and 20 mM p-mercaptoethanol 
was determined.
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FIGURE 9. Standard Curve of Recovered Exogenous AA Added to 
Liver Homogenates One mM AA was added to liver 
homogenates in various amounts and recovered in a linear fashion 










FIGURE 10. Standard Curve of Recovery of Exogenous AA Added 
to Brain Homogenates One mM AA was added to brain 














FIGURE 11. Standard Curve of Recovery of AA in Kidney
Homogenates One mM AA was added in varying amounts to kidney 












FIGURE 12. Standard Curve of Recoveries of DHAA Adds*? to
Buffer DHAA was added to buffer in various amounts and recovered 















FIGURE 13. Standard Curve of Recoveries of DHAA in Liver
Homogenates DHAA was added to liver homogenates in various 















FIGURE 14. Standard Curve of Recovery of DHAA Added to Brain 
Homogenates DHAA was added to brain homogenates in varying 























FIGURE 15. Standard Curve of Recovery of DHAA From Kidney 
Homogenates DHAA was added to kidney homogenates in 















FIGURE 16. Endogenous AA in Diabetic and Control Rat Tissues
Endogenous AA levels in diabetic and nondiabetic rat brain, kidney, 
and liver tissues were determined using HPLC-EC.


















FIGURE 17. Endogenous Measurements of DHAA in Diabetic 
and Nondiabetic Rat Tissues Endogenous DHAA levels in
diabetic and nondiabetic rat liver, brain, and kidney tissues were 
determined by measurement of total AA and calculation of DHAA 
based on these measurements and AA measurements.
* p< 0.05 for diabetic compared to nondiabetic measurements







FIGURE 18 A & B. Endogenous Measurements of AA and DHAA in 
Diabetic and Nondiabetic Rat Adrenal Glands Figure 18 A 
presents the measurement of endogenous AA in diabetic and 
nondiabetic rat adrenal glands. Figure 18 B presents the 
measurements of endogenous DHAA in diabetic and nondiabetic rat 
adrenal glands calculated from measured total AA (AA + DHAA) and 
endogenous AA.
* p < 0.05 for diabetic compared to nondiabetic measurements





























.. *.. . . .— ....... ».—.1
CONTROL DIABETIC
(B)
FIGURE 19. R ecovery o f Exogenous AA and DHAA One mM AA and 1
mM DHAA were added to diabetic and nondiabetic tissues used in the analysis 
of endogenous levels of AA and DHAA. Recoveries in brain, kidney and liver 
tissues were evaluated and grouped into diabetic and nondiabetic 
measurements.
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KEY TO ABBREVIATIONS USED IN TEXT
Compounds
AA Ascorbic acid
APR Ascorbate free radical





MFO Mixed function oxidase
n 2 Nitrogen
NADH Nicotinamide adenine 
dinucleotinde, reduced form
PAM Peptidylglycine a-amidating 
monooxygenase
TCA Trichloroacetic acid
















E1 /2 Half-wave potential
EC Electrochemical
9 Acceleration of gravity
HPLC High-performance liquid 
chromatography
pH -log hydrogen ion 
concentration
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